Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

On the chromatin slide, the possibilities are endless

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Alex125 Member Profile
 
Followed By 5
Posts 185
Boards Moderated 0
Alias Born 09/16/10
160x600 placeholder
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:41:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:36:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:31:15 PM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 8/4/2021 7:00:00 AM
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 GlobeNewswire Inc. - 8/4/2021 7:00:00 AM
Cassava Sciences drags rivals lower amid concerns over its Alzheimer’s drug Seeking Alpha - 7/30/2021 9:03:44 AM
Anavex Life Sciences rises on positive data for Alzheimer’s therapy in mouse study Seeking Alpha - 7/29/2021 7:46:45 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease GlobeNewswire Inc. - 7/29/2021 7:00:00 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/20/2021 7:00:00 AM
Alzheimer's drug players shake off concerns from Biogen aducanunab probe Seeking Alpha - 7/12/2021 10:20:38 AM
CEO Presenting on the Second Emerging Growth / Investors Hub Joint Conference on July 7. InvestorsHub NewsWire - 7/5/2021 7:00:00 AM
WNRS Upgraded To BUY InvestorsHub NewsWire - 7/1/2021 9:36:27 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
Anavex posts the sharpest one-day loss in over seven months Seeking Alpha - 6/29/2021 4:49:18 PM
Anavex posts the sharpest one-day loss in over seven months Seeking Alpha - 6/29/2021 4:47:49 PM
Alex125   Thursday, 04/15/21 10:35:37 AM
Re: Steady_T post# 307121
Post # of 330512 
On the chromatin slide, the possibilities are endless since it alters mRNA function. IMHO many pathological entities will benefit from Anavex. Many more diseases will come on Anavex's way when it proves its efficacy.
One thing that striked me is the possibility of improving Parkinson's itself not only Parkinson's dementia.
This means that the biochemical improvement will affect many other medical entities.
I let my imagination fly.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences